Rein Therapeutics, Inc. (RNTX): Total Assets
$24.16M
As of 2025-12-31
$65.97M
As of 2026-06-30
+3.2%
3-year compound annual growth
+8.1%
5-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $24.16M | -61.2% | 2026-03-26, Balance as of period end |
| 2024-12-31 | $62.19M | -41.3% | 2026-03-26, Balance as of period end |
| 2023-12-31 | $106.01M | +381.7% | 2025-04-07, Balance as of period end |
| 2022-12-31 | $22.01M | -54.6% | 2024-04-15, Balance as of period end |
| 2021-12-31 | $48.48M | +196.7% | 2023-03-20, Balance as of period end |
| 2020-12-31 | $16.34M | -38.3% | 2022-03-28, Balance as of period end |
| 2019-12-31 | $26.47M | -12.7% | 2021-03-24, Balance as of period end |
| 2018-12-31 | $30.31M | -42.5% | 2020-03-30, Balance as of period end |
| 2017-12-31 | $52.69M | +139.3% | 2019-03-29, Balance as of period end |
| 2016-12-31 | $22.02M | n/a | 2018-04-02, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Rein Therapeutics, Inc. (RNTX) | 2025-12-31 | $24.16M | -61.2% |
| Abbott Laboratories (ABT) | 2025-12-31 | $86.71B | +6.5% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $90.04B | -2.8% |
| TherapeuticsMD, Inc. (TXMD) | 2025-12-31 | $37.66M | -3.0% |
| Eli Lilly & Co (LLY) | 2025-12-31 | $112.48B | +42.9% |
| Pfizer Inc (PFE) | 2025-12-31 | $208.16B | -2.5% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $199.21B | +10.6% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $261.15M | +8.4% |
| Merck & Co., Inc. (MRK) | 2025-12-31 | $136.87B | +16.9% |
Compare RNTX, ABT, BMY, TXMD side by side · Screen every company in Pharmaceutical Preparations ↗